A 7-month-old previously healthy male infant presents with a 15-minute generalized convulsive seizure triggered by fever (39.5°C) following vaccination. The seizure was hemiclonic, progressing to bilateral tonic-clonic activity. EEG obtained 2 weeks later shows the pattern marked **C** in the diagram. Genetic testing confirms a de novo loss-of-function mutation in SCN1A. Which of the following drug combinations represents the most appropriate first-line treatment for this condition?

Question

Accepted Answer

C. Valproate and clobazam. ## Why Valproate and clobazam is right

The EEG pattern marked **C** — photosensitive polyspike-wave — is the hallmark EEG finding in Dravet syndrome (SMEI), a severe genetic epileptic encephalopathy caused by SCN1A mutations encoding the voltage-gated sodium channel Nav1.1. Loss of Nav1.1 function in inhibitory GABAergic interneurons causes disinhibition and hyperexcitability. The clinical presentation (febrile hemiclonic seizure in a previously healthy 7-month-old, genetic confirmation of SCN1A mutation) is pathognomonic for Dravet syndrome. First-line treatment is the combination of valproate and clobazam, which work synergistically to control seizures without worsening the underlying channelopathy (Nelson Pediatrics 21e; Lancet Neurol 2017).

## Why each distractor is wrong

- **Carbamazepine and lamotrigine**: Both are sodium channel blockers that PARADOXICALLY WORSEN seizures in Dravet syndrome by further blocking the already-deficient Nav1.1 channels in interneurons. These drugs are explicitly contraindicated and must be avoided in SCN1A-related epilepsy.
- **Phenytoin and oxcarbazepine**: Phenytoin is a sodium channel blocker and is contraindicated for the same reason as carbamazepine. Oxcarbazepine, a structural analog of carbamazepine, also blocks sodium channels and worsens Dravet seizures. Both are harmful in this context.
- **Levetiracetam and topiramate**: While levetiracetam is not contraindicated, it is not first-line for Dravet syndrome. Topiramate has some utility as adjunctive therapy but is not part of the standard first-line regimen. Valproate + clobazam remains the gold standard initial treatment.

**High-Yield:** In Dravet syndrome (SCN1A mutation), AVOID all sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine); use VALPROATE + CLOBAZAM as first-line, and add STIRIPENTOL for triple therapy if needed.

[cite: Nelson Pediatrics 21e; Lancet Neurol 2017]

Answer

A. Phenytoin and oxcarbazepine

Answer

B. Carbamazepine and lamotrigine

Answer

D. Levetiracetam and topiramate

Explanation

Why Valproate and clobazam is right

Why each distractor is wrong

Practice similar questions